Pfizer remains a strong buy with rising oncology drug sales and solid dividend yield despite FDA leadership changes.

Pfizer continues to be favored by investors due to its strong performance in the oncology drug market, highlighted by a 16.3% quarterly and 38.7% yearly sales increase of Padcev, driven by demand in combination with Merck's Keytruda. Despite recent FDA leadership changes, including the resignation of Commissioner Marty Makary, Pfizer's financial metrics remain attractive with a non-GAAP P/E ratio of 8.6x and a 6.8% dividend yield. The company’s promising drug pipeline and steady sales growth support a 'Strong Buy' rating from analysts, indicating confidence in its future performance.